Biotech Values

[apljack]

JAV: Completely expected results here, no downside (unless readers were expecting a stat sig superior effect when compared to ketorolac or more vigorous wording on lower side effect issues).

The co. revealed that they would not be ready for the NDA until at least June, which will leave the co. dangling for money. The recent layoffs will help the cash burn and the winding down of the PMI-150 trial will also help (if rapid enrollment continues), but we will not get any respect until a partner has been announced.

Any other upside? It would be nice to hear continued acceleration of use in the UK.

aj